{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:21:36Z","timestamp":1794608496326,"version":"4.9.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"government of Mexico"},{"name":"EU\/EFPIA\/Innovative Medicines Initiative"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.vaccine.2019.01.086","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T18:05:27Z","timestamp":1549908327000},"page":"1630-1637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production"],"prefix":"10.1016","volume":"37","author":[{"given":"Jos\u00e9","family":"Herrera-Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Signorazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Holtrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"de Vries-Idema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2646-5143","authenticated-orcid":false,"given":"Anke","family":"Huckriede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.01.086_b0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.20506\/rst.28.1.1879","article-title":"Pandemic influenza\u2013including a risk assessment of H5N1","volume":"28","author":"Taubenberger","year":"2009","journal-title":"Rev Sci Tech"},{"key":"10.1016\/j.vaccine.2019.01.086_b0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2019.01.086_b0015","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/CMR.00097-12","article-title":"Traditional and new influenza vaccines","volume":"26","author":"Wong","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2019.01.086_b0020","unstructured":"The European Agency for the Evaluation of Medical Products. Note for guidence on harmonisation of requirements for influenza vaccines; 1997. p. 19. www.Eudra.Org\/Emea.Html."},{"key":"10.1016\/j.vaccine.2019.01.086_b0025","unstructured":"WHO. Annex 4 - Recommendations to assure the quality, safety and efficacy of influenza vaccines (human, live attenuated) for intranasal administration 2013;977:189\u2013240."},{"key":"10.1016\/j.vaccine.2019.01.086_b0030","unstructured":"Edwards K, Lynfield R, Chair Janet Englund A, Kotloff K, Levy O, Long S, et al. Summary Minutes - 142nd Vaccines and Related Biological Products Advisory Committee Meeting; 2016."},{"key":"10.1016\/j.vaccine.2019.01.086_b0035","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1128\/am.19.2.290-294.1970","article-title":"Effect of formalin, beta-propiolactone, merthiolate, and ultraviolet light upon influenza virus infectivity chicken cell agglutination, hemagglutination, and antigenicity","volume":"19","author":"Goldstein","year":"1970","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.vaccine.2019.01.086_b0040","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0264-410X(91)90125-P","article-title":"Noskov FS. Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of fl-propiolactone","volume":"9","author":"Budowsky","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.086_b0045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbamem.2013.09.021","article-title":"Treatment of influenza virus with beta-propiolactone alters viral membrane fusion","volume":"1838","author":"Bonnafous","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.vaccine.2019.01.086_b0050","doi-asserted-by":"crossref","first-page":"36198","DOI":"10.1074\/jbc.M111.279232","article-title":"Reactions of beta-propiolactone with nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses","volume":"286","author":"Uittenbogaard","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2019.01.086_b0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1863-2378.2007.01029.x","article-title":"Inactivation of avian influenza viruses by chemical agents and physical conditions: a review","volume":"54","author":"De Benedictis","year":"2007","journal-title":"Zoonoses Public Health"},{"key":"10.1016\/j.vaccine.2019.01.086_b0060","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/bc050340f","article-title":"Identification of formaldehyde-induced modifications in proteins: reactions with insulin","volume":"17","author":"Metz","year":"2006","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.vaccine.2019.01.086_b0065","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jviromet.2014.07.003","article-title":"Hydrogen peroxide inactivation of influenza virus preserves antigenic structure and immunogenicity","volume":"207","author":"Dembinski","year":"2014","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2019.01.086_b0070","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1099\/vir.0.018168-0","article-title":"Effect of inactivation method on the cross-protective immunity induced by whole \u201ckilled\u201d influenza A viruses and commercial vaccine preparations","volume":"91","author":"Furuya","year":"2010","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.01.086_b0075","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2307\/1591214","article-title":"Evaluation of different methods of inactivation of Newcastle disease virus and avian influenza virus in egg fluids and serum","volume":"35","author":"King","year":"1991","journal-title":"Avian Dis"},{"key":"10.1016\/j.vaccine.2019.01.086_b0080","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0140-6736(03)14854-4","article-title":"Influenza","volume":"362","author":"Nicholson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.01.086_b0085","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1128\/JCM.02045-09","article-title":"Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling","volume":"48","author":"Jonges","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2019.01.086_b0090","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1016\/j.vaccine.2011.04.029","article-title":"Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization","volume":"29","author":"Audouy","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.086_b0095","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0003-2697(77)90043-4","article-title":"A simplification of the protein assay method of Lowry which is more generally applicable","volume":"83","author":"Peterson","year":"1977","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2019.01.086_b0100","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3390\/ijms18040708","article-title":"\u201cBligh and Dyer\u201d and Folch methods for solid\u2013liquid\u2013liquid extraction of lipids from microorganisms. Comprehension of solvatation mechanisms and towards substitution with alternative solvents","volume":"18","author":"Breil","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2019.01.086_b0105","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1073\/pnas.65.4.1105","article-title":"Models of structure of the envelope of influenza virus","volume":"65","author":"Tiffany","year":"1970","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.01.086_b0110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","article-title":"Determination of 50% endpoint titer using a simple formula","volume":"5","author":"Ramakrishnan","year":"2016","journal-title":"World J Virol"},{"key":"10.1016\/j.vaccine.2019.01.086_b0115","doi-asserted-by":"crossref","first-page":"e30898","DOI":"10.1371\/journal.pone.0030898","article-title":"Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: The role of viral membrane fusion activity","volume":"7","author":"Budimir","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.01.086_b0120","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small-antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2019.01.086_b0125","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1016\/j.vaccine.2012.07.036","article-title":"Effect of viral membrane fusion activity on antibody induction by influenza H5N1 whole inactivated virus vaccine","volume":"30","author":"Geeraedts","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.086_b0130","doi-asserted-by":"crossref","first-page":"8280","DOI":"10.1016\/j.vaccine.2010.10.007","article-title":"The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenza-specific cytotoxic T lymphocytes","volume":"28","author":"Budimir","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.086_b0135","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2019.01.086_b0140","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.4049\/jimmunol.163.9.4673","article-title":"TH cells primed during influenza virus infection provide help for qualitatively distinct antibody responses to subsequent immunization","volume":"163","author":"Marshall","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.01.086_b0145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.18869\/acadpub.vacres.3.7.26","article-title":"Evaluation of the effects of concentration, duration and temperature of incubation with Beta-Propiolactone on inactivation of cell-derived rabies virus","volume":"3","author":"Eftekhari","year":"2016","journal-title":"Vaccine Res"},{"key":"10.1016\/j.vaccine.2019.01.086_b0150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jviromet.2015.05.004","article-title":"Evaluation of different inactivation methods for high and low pathogenic avian influenza viruses in egg-fluids for antigen preparation","volume":"222","author":"Pawar","year":"2015","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2019.01.086_b0155","first-page":"416","article-title":"Effect of physico-chemical factors on survival of avian influenza virus (H7N3 Type)","volume":"3","author":"Muhmmad","year":"2001","journal-title":"Int J Agric Biol"},{"key":"10.1016\/j.vaccine.2019.01.086_b0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-3083.2005.01633.x","article-title":"Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB\/c mice","volume":"62","author":"Hovden","year":"2005","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2019.01.086_b0165","doi-asserted-by":"crossref","first-page":"e1000138","DOI":"10.1371\/journal.ppat.1000138","article-title":"Superior immunogenicity of inactivated whole virus h5n1 influenza vaccine is primarily controlled by toll-like receptor signalling","volume":"4","author":"Geeraedts","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2019.01.086_b0170","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3390\/v7020666","article-title":"Evaluation of virus inactivation by formaldehyde to enhance biosafety of diagnostic electron microscopy","volume":"7","author":"M\u00f6ller","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2019.01.086_b0175","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0378-1135(93)90027-5","article-title":"Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines","volume":"37","author":"Williams","year":"1993","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2019.01.086_b0180","doi-asserted-by":"crossref","first-page":"e0150700","DOI":"10.1371\/journal.pone.0150700","article-title":"Influenza vaccine manufacturing: effect of inactivation, splitting and site of manufacturing. Comparison of influenza vaccine production processes","volume":"11","author":"Kon","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.01.086_b0185","doi-asserted-by":"crossref","first-page":"13675","DOI":"10.1021\/la2027175","article-title":"Effect of the \u03b2-propiolactone treatment on the adsorption and fusion of influenza A\/Brisbane\/59\/2007 and A\/New Caledonia\/20\/1999 virus H1N1 on a dimyristoylphosphatidylcholine\/ganglioside GM3 mixed phospholipids monolayer at the air-water interface","volume":"27","author":"Desbat","year":"2011","journal-title":"Langmuir"},{"key":"10.1016\/j.vaccine.2019.01.086_b0190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1750-2659.2008.00038.x","article-title":"Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs","volume":"2","author":"Geeraedts","year":"2008","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.vaccine.2019.01.086_b0195","doi-asserted-by":"crossref","unstructured":"Luo M. Influenza Virus Entry, Springer, Boston, MA; 2012, p. 201\u201321. http:\/\/doi.org\/10.1007\/978-1-4614-0980-9_9.","DOI":"10.1007\/978-1-4614-0980-9_9"},{"key":"10.1016\/j.vaccine.2019.01.086_b0200","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1002\/pmic.201300096","article-title":"Surface modifications of influenza proteins upon virus inactivation by \u03b2-propiolactone","volume":"13","author":"She","year":"2013","journal-title":"Proteomics"},{"key":"10.1016\/j.vaccine.2019.01.086_b0205","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1128\/JVI.01927-14","article-title":"Variations in pH sensitivity, acid stability, and fusogenicity of three influenza virus H3 subtypes","volume":"89","author":"Costello","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.01.086_b0210","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0264-410X(85)90109-4","article-title":"Stability of infectious influenza A viruses at low pH and at elevated temperature","volume":"3","author":"Scholtissek","year":"1985","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.086_b0215","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/293479a0","article-title":"Biochemical identification of viruses causing the 1981 outbreaks of foot and mouth disease in the UK","volume":"293","author":"King","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.01.086_b0220","first-page":"103","article-title":"Review of accidents caused by incomplete inactivation of viruses","volume":"81","author":"Brown","year":"1993","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2019.01.086_b0225","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jviromet.2004.06.006","article-title":"Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV","volume":"121","author":"Darnell","year":"2004","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2019.01.086_b0230","first-page":"1","article-title":"Analysis of antigen conservation and inactivation of gamma-irradiated avian influenza virus subtype H9N2","author":"Salehi","year":"2018","journal-title":"Acta Microbiol Immunol Hung"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19301847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19301847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:30:41Z","timestamp":1759401041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19301847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0264410X19301847"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.01.086","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.01.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}